GlaxoSmithKline and Johnson & Johnson returned to join Sanofi in backing the biopharmaceutical company's series B round, bringing its total funding to more than $65m.
US-based biopharmaceutical company Navitor Phatmaceuticals has closed a $33m series B round co-led by Brace Pharma Capital, which acts as a subsidiary of Brazil-based pharmaceutical firm EMS, and undisclosed high net worth investors.
The round also included Sanofi-Genzyme BioVentures, Johnson & Johnson Innovation – JJDC and SR One, the respective corporate venturing arms of pharmaceutical companies Sanofi, Johnson & Johnson and GlaxoSmithKline.
Venture capital firms Polaris Partners, Atlas Venture and Remeditex Ventures also took part in the round.
Navitor is…
